Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sunesis Pharmaceuticals, a biopharmaceutical company focused on small molecule therapeutics, has received a $500,000 milestone payment from Biogen Idec relating to the discovery of novel Raf kinase inhibitors for the treatment of cancer.
Subscribe to our email newsletter
In September 2004 the companies entered into a collaboration to discover and develop small molecule cancer therapeutics targeting kinases, a family of cell signaling enzymes that play a major role in the progression of cancer. The milestone payment was triggered by identifying compounds with specific predetermined preclinical characteristics.
“We are pleased by the continued progress being made by our teams and the joint research committee in the advancement of kinase inhibitors toward the clinic,” said Daniel Swisher, Sunesis’ CEO. “This program is proceeding on course and we anticipate selecting the first safety assessment candidates from this collaboration next year.”